Lipella Pharmaceuticals Stock Forum

$Lipella Pharmaceuticals (LIPO.US)$
09/10/2024 - 22:47
PITTSBURGH, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced that CEO Jonathan Kaufman, PhD will be presenting at the 2024 Maxim Healthcare Virtual Summit that is being held on October 15...

$Lipella Pharmaceuticals (LIPO.US)$
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus | LIPO Stock News

$ParaZero Technologies (PRZO.US)$ $PharmaCyte Biotech (PMCB.US)$ $Jeffs' Brands (JFBR.US)$ $Lipella Pharmaceuticals (LIPO.US)$ $Steakholder Foods (STKH.US)$ $Banzai International (BNZI.US)$ $Indaptus Therapeutics (INDP.US)$ $Moolec Science (MLEC.US)$ $Phoenix Motor (PEV.US)$ $EDC Publishing (EDUC.US)$ $Gogoro (GGR.US)$
📊⚡️📊

$Lipella Pharmaceuticals (LIPO.US)$
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
Lipella Pharmaceuticals (Nasdaq: LIPO) has reported encouraging early tolerability results in its Phase 2a trial of LP-310 for Oral Lichen Planus (OLP). Three participants have completed the four-week treatment with the oral rinse, showing good tolerability and no unpleasant taste. The multi-center study is evaluating the safety, tolerab...

$Lipella Pharmaceuticals (LIPO.US)$ Reuters· just
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus